OBJECTIVE: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas. METHODS: c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation. RESULTS: 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients. CONCLUSIONS: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.
OBJECTIVE: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas. METHODS:c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation. RESULTS: 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients. CONCLUSIONS: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.
Authors: Tatyana A Grushko; James J Dignam; Soma Das; Anne M Blackwood; Charles M Perou; Karin K Ridderstråle; Kristin N Anderson; Min-Jie Wei; April J Adams; Fitsum G Hagos; Lise Sveen; Henry T Lynch; Barbara L Weber; Olufunmilayo I Olopade Journal: Clin Cancer Res Date: 2004-01-15 Impact factor: 12.531
Authors: Camilo Adem; Cheryl L Soderberg; Kari Hafner; Carol Reynolds; Jeffrey M Slezak; Colleen S Sinclair; Thomas A Sellers; Daniel J Schaid; Fergus Couch; Lynn C Hartmann; Robert B Jenkins Journal: Genes Chromosomes Cancer Date: 2004-09 Impact factor: 5.006
Authors: Bruce G Haffty; Analene Hauser; Doo Ho Choi; Nicole Parisot; David Rimm; Bonnie King; Darryl Carter Journal: Cancer Date: 2004-01-15 Impact factor: 6.860
Authors: Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale Journal: Mol Oncol Date: 2010-04-24 Impact factor: 6.603
Authors: Linda E Kelemen; Xianshu Wang; Zachary S Fredericksen; V Shane Pankratz; Paul D P Pharoah; Shahana Ahmed; Alison M Dunning; Douglas F Easton; Robert A Vierkant; James R Cerhan; Ellen L Goode; Janet E Olson; Fergus J Couch Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05-19 Impact factor: 4.254
Authors: Lei Yu; Michael J Hitchler; Wenqing Sun; Ehab H Sarsour; Prabhat C Goswami; Aloysius J Klingelhutz; Frederick E Domann Journal: J Oncol Date: 2009-12-24 Impact factor: 4.375